Roivant parlays a $450M chunk of equity in biotech buyout, grabbing a computational group to drive discovery work
New Roivant CEO Matt Gline has crafted an all-equity upfront deal to buy out a Boston-based biotech that has been toiling for several years now at building a supercomputing-based computational platform to design new drugs. And he’s adding it to the Erector set of science operations that are being built up to support their network of biotech subsidiaries with an eye to growing the pipeline in a play to create a new kind of pharma company.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.